CEO SUMMARY: Many of the recently issued reimbursement rates for molecular diagnostic tests are inadequate and in fact are lower than the cost of running the tests, lab experts say. Smaller laboratories that specialize in developing and selling molecular tests could be forced to close. As many as 20 or more molecular labs operate in California and are facing the prospect of appealing the low rates and awaiting a decision on these appeals.
Read full article (PDF download)
No part of this article may be reproduced or posted online without permission from THE DARK REPORT. This document contains confidential copyrighted material.
